By a News Reporter-Staff News Editor at Biotech Week -- Investigators discuss new findings in Immunology. According to news originating from Nagoya, Japan, by NewsRx correspondents, research stated, "Although short-term graft survival has been improved by recent desensitization protocols including B cell depletion therapy, little is known about risk factors of chronic antibody-mediated rejection (CAMR) in HLA-incompatible (HLA-I) renal transplantation (RTx). Twenty-six HLA-I RTx with positive donor-specific antibodies (DSA) and negative T cell cytotoxic crossmatches were compared with 88 ABO-incompatible (ABO-I) and 207 ABO-identical/compatible (ABO-Id/C) RTx."
Our news journalists obtained a quote from the research from Nagoya University, "The desensitization therapy consisted of mycophenolate mofetil, rituximab and double-filtration plasmapheresis. Protocol biopsies within 1 year revealed subclinical CAMR in 36% of HLA-I, 5% of ABO-I and 3% of ABO-Id/C, although clinical acute AMR was observed in 8%, 3% and 1%, respectively. The incidence of CAMR was not different between class I and class II DSA. Most of class I DSA (94%) changed to negative I year after RTx, whereas 77% of class II DSA remained positive. In addition, the remaining DRB +/- DQB DSA caused CAMR in 80% of patients, while DQB DSA alone did not. The progress of subclinical CAMR within 1 year could not be circumvented by rituximab."
According to the news editors, the research concluded: "Sustained class II (DRB +/- DQB) DSA detection after RTx may pose a potential risk for developing CAMR, but negative change in class I DSA could also elicit CAMR."
For more information on this research see: Frequent development of subclinical chronic antibody-mediated rejection within 1 year after renal transplantation with pre-transplant positive donor-specific antibodies and negative CDC crossmatches. Human Immunology, 2013;74(9):1111-1118. Human Immunology can be contacted at: Elsevier Science Inc, 360 Park Ave South, New York, NY 10010-1710, USA. (Elsevier - www.elsevier.com; Human Immunology - www.elsevier.com/wps/product/cws_home/505763)
The news correspondents report that additional information may be obtained from S. Yamanaga, Nagoya University, Sch Med, Dept. of Surg 2, Showa Ku, Nagoya, Aichi 4668550, Japan. Additional authors for this research include Y. Watarai, T. Yamamoto, M. Tsujita, T. Hiramitsu, K. Nanmoku, N. Goto, A. Takeda, K. Morozumi, A. Katayama, H. Saji, K. Uchida and T. Kobayashi (see also Immunology).
Keywords for this news article include: Asia, Antineoplastic Monoclonal Antibodies, Antirheumatics, Biotechnology, Japan, Drugs, Nagoya, Kidney, Therapy, Rituximab, Immunology, Nephrology, Blood Proteins, Immunogenetics, Immunoglobulins, Medical Devices, CD20 Monoclonal Antibodies, Tyrosine Kinase Inhibitors
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2013, NewsRx LLC